TY - JOUR
KW - Humans
KW - Cholesterol, LDL
KW - *Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use
KW - *Diabetes Mellitus, Type 2/complications/drug therapy/epidemiology
KW - *Cardiovascular Diseases/drug therapy
KW - Retrospective Studies
KW - Cholesterol
KW - *Atherosclerosis/complications/epidemiology
KW - *Stroke/epidemiology/etiology
KW - United Kingdom/epidemiology
KW - Low-density lipoprotein cholesterol
KW - Major adverse cardiovascular events
KW - atherosclerotic cardiovascular disease
KW - lipid-lowering therapy
KW - Type 2 diabetes
AU - C. Morgan
AU - A. Durand
AU - T. McCormack
AU - E. Hughes
AU - T. Berni
AU - R. Lahoz
AD - Epidemiology, Human Data Sciences, Cardiff, UK chris.morgan@humandatasciences.com.
Novartis Pharmaceuticals, London, UK.
Institute of Clinical and Applied Health Research, Hull York Medical School, Hull, UK.
Sandwell and West Birmingham Hospitals NHS Trust, Birmingham, Birmingham, UK.
Epidemiology, Human Data Sciences, Cardiff, UK.
Novartis Pharma AG, Basel, Switzerland.
AN - 38030254
BT - BMJ Open
C2 - PMC10689406
DO - 10.1136/bmjopen-2022-064541
DP - NLM
ET - 2023/11/30
LA - eng
M1 - 11
N1 - 2044-6055
Morgan, Christopher Ll
Orcid: 0000-0001-8796-7406
Durand, Adeline
McCormack, Terry
Hughes, Elizabeth
Berni, Thomas R
Lahoz, Raquel
Journal Article
England
BMJ Open. 2023 Nov 29;13(11):e064541. doi: 10.1136/bmjopen-2022-064541.
PY - 2023
SN - 2044-6055
EP - e064541
T2 - BMJ Open
TI - Risk of major adverse cardiovascular events associated with elevated low-density lipoprotein cholesterol in a population with atherosclerotic cardiovascular disease with and without type 2 diabetes: a UK database analysis using the CPRD
VL - 13
ER -